A Randomised tRial of Expedited transfer to a cardiac arrest centre for non-ST elevation ventricular fibrillation out-of-hospital cardiac arrest: The ARREST pilot randomised trial. by Patterson, Tiffany et al.
Patterson, T; Perkins, GD; Joseph, J; Wilson, K; Van Dyck, L;
Robertson, S; Nguyen, H; McConkey, H; Whitbread, M; Fothergill,
R; Nevett, J; Dalby, M; Rakhit, R; MacCarthy, P; Perera, D; Nolan,
JP; Redwood, SR (2017) A Randomised tRial of Expedited transfer
to a cardiac arrest centre for non-ST elevation ventricular fibrillation
out-of-hospital cardiac arrest: The ARREST pilot randomised trial.
Resuscitation. ISSN 0300-9572 DOI: 10.1016/j.resuscitation.2017.01.020
Downloaded from: http://researchonline.lshtm.ac.uk/3482720/
DOI: 10.1016/j.resuscitation.2017.01.020
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
Please cite this article in press as: Patterson T, et al. A Randomised tRial of Expedited transfer to a cardiac arrest centre for
non-ST elevation ventricular ﬁbrillation out-of-hospital cardiac arrest: The ARREST pilot randomised trial. Resuscitation (2017),
http://dx.doi.org/10.1016/j.resuscitation.2017.01.020
ARTICLE IN PRESSG ModelRESUS-7053; No. of Pages 7
Resuscitation xxx (2017) xxx–xxx
Contents lists available at ScienceDirect
Resuscitation
journa l homepage: www.e lsev ier .com/ locate / resusc i ta t ion
Clinical  paper
A  Randomised  tRial  of  Expedited  transfer  to  a  cardiac  arrest  centre  for
non-ST  elevation  ventricular  ﬁbrillation  out-of-hospital  cardiac
arrest:  The  ARREST  pilot  randomised  trial
Tiffany  Pattersona,  Gavin  D.  Perkinsb, Jubin  Josepha, Karen  Wilsona, Laura  Van  Dyckc,
Steven  Robertsonc, Hanna  Nguyena, Hannah  McConkeya, Mark  Whitbreadd,
Rachael  Fothergill d, Joanne  Nevettd,  Miles  Dalbye,  Roby  Rakhit f, Philip  MacCarthyg,
Divaka  Pereraa,  Jerry  P.  Nolanh, Simon  R.  Redwooda,∗
a Cardiovascular Division, The Rayne Institute BHF Centre of Research Excellence, King’s College London, St. Thomas’ Hospital, London, UK
b Warwick Clinical Trials Unit and Heart of England NHS Foundation Trust, Warwick Medical School, University of Warwick, Coventry, UK
c London School Of Hygiene and Tropical Medicine Clinical Trials Unit, London, UK
d London Ambulance Service, London, UK
e Department of Cardiology, Royal Brompton and Hareﬁeld NHS Foundation Trust, Middlesex, UK
f Department of Cardiology, Royal Free NHS Foundation Trust, London, UK
g Department of Cardiology, King’s College Hospital NHS Foundation Trust, London,UK
h School of Clinical Sciences, University of Bristol and Department of Anaesthesia, Royal United Hospital, Bath, UK
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 22 October 2016
Received in revised form 13 January 2017
Accepted 24 January 2017
Keywords:
Out-of-hospital cardiac arrest
Cardiac resuscitation centre
Coronary angiography
a  b  s  t  r  a  c  t
Background:  Wide  variation  exists  in  inter-hospital  survival  from  out-of-hospital  cardiac  arrest  (OHCA).
Regionalisation  of  care  into  cardiac  arrest centres  (CAC)  may  improve  this.  We  report  a pilot  randomised
trial  of expedited  transfer  to a  CAC  following  OHCA  without  ST-elevation.  The  objective  was  to assess  the
feasibility  of performing  a large-scale  randomised  controlled  trial.
Methods:  Adult  witnessed  ventricular  ﬁbrillation  OHCA  of  presumed  cardiac  cause  were  randomised  1:1
to  either:  (1)  treatment:  comprising  expedited  transfer  to a CAC  for  goal-directed  therapy  including access
to  immediate  reperfusion,  or  (2)  control:  comprising  current  standard  of  care involving  delivery  to the
geographically  closest  hospital.  The feasibility  of  randomisation,  protocol  adherence  and data  collection
of  the  primary  (30-day  all-cause  mortality)  and  secondary  (cerebral  performance  category  (CPC))  and
in-hospital  major  cardiovascular  and  cerebrovascular  events  (MACCE)  clinical  outcome  measures  were
assessed.
Results:  Between  November  2014  and April  2016,  118  cases  were  screened,  of  which  63  patients  (53%) met
eligibility  criteria  and  40 of  the  63 patients  (63%)  were  randomised.  There  were  no  protocol  deviations  in
the treatment  arm.  Data  collection  of  primary  and  secondary  outcomes  was  achieved  in  83%. There  was
no difference  in baseline  characteristics  between  the  groups:  30-day  mortality  (Intervention  9/18,  50%
vs.  Control  6/15, 40%;  P =  0.73),  CPC  1/2 (Intervention:  9/18,  50%  vs.  Control  7/14, 50%; P >  0.99)  or  MACCE
(Intervention:  9/18,  50%  vs.  Control  6/15,  40%;  P =  0.73).
Conclusions:  These  ﬁndings  support  the feasibility  and acceptability  of  conducting  a  large-scale  ran-
domised  controlled  trial of  expedited  transfer  to CAC  following  OHCA  to  address  a  remaining  uncertainty
in post-arrest  care.
© 2017  Elsevier  B.V.  All  rights  reserved.
 A Spanish translated version of the abstract of this article appears as Appendix
in  the ﬁnal online version at doi:10.1016/j.resuscitation.2017.01.020.
∗ Corresponding author at: Cardiovascular Department, Kings College London, St.
Thomas Hospital, London SE1 7EH, UK.
E-mail address: simon.redwood@gstt.nhs.uk (S.R. Redwood).
Introduction
Out-of-hospital cardiac arrest (OHCA) is a global public health
issue. There are 60,000 OHCA per year in the United Kingdom
and over 400,000 in the United States1–3 There is wide varia-
tion in both regional and inter-hospital survival rates from OHCA
and overall survival remains poor, with a reported average of
http://dx.doi.org/10.1016/j.resuscitation.2017.01.020
0300-9572/© 2017 Elsevier B.V. All rights reserved.
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7%.4 The adoption of systematic approaches to post-resuscitation
care may  improve long-term survival from OHCA.5,6 Regionalisa-
tion of care into specialist centres has played a vital role in the
management of time-critical illnesses through concentration of
services and greater provider experience.7–14 Coronary artery dis-
ease is responsible for >70% of OHCA, with an acute occlusion
demonstrated in 50% of consecutive patients taken immediately
to coronary angiography.15 Multi-faceted interventions including
early cardiopulmonary resuscitation (CPR) and deﬁbrillation, fol-
lowed by timely reperfusion are associated with reduced risk of
re-arrest, reduced myocardial dysfunction and thus improved out-
comes following cardiac arrest from ST-elevation (STE) myocardial
infarction.16–18 The International Liaison Committee on Resusci-
tation (ILCOR) suggests transport of all post-arrest patients to
a cardiac arrest centre (CAC) with 24/7 access to interventional
cardiology facilities to manage the ensuing cardiovascular dys-
function and to diagnose and treat the underlying cause with a
view to increasing survival.19–22 The management of cardiac arrest
survivors without STE, however, is controversial, with a less time-
sensitive approach to cardiac catheterisation. Because of the lack of
randomised data, there has been variable uptake of such a strategy
amongst the interventional cardiology community. ILCOR states
that randomised trials are therefore essential in this population to
determine if timely delivery to a CAC improves survival.23 How-
ever, the coordination of this is complex and close interaction
is necessary between centres and ambulance services and inter-
nally between the emergency department, cardiologists and the
critical care team. We  performed A (pilot) Randomised tRial of
Expedited transfer to a cardiac arrest centre for non-ST elevation
OHCA (ARREST) of presumed cardiac cause to assess the safety and
feasibility of conducting a large-scale randomised controlled trial
in patients without STE.
Methods
This was a pilot multi-centre prospective randomised controlled
trial undertaken in London, United Kingdom by London Ambulance
Service (LAS) and St. Thomas Hospital (for system characteristics
see online supplemental information). All adult witnessed out-
of-hospital pulseless ventricular tachycardia (VT) or ventricular
ﬁbrillation (VF) cardiac arrests without obvious non-cardiac cause
(trauma, drowning, suicide, poisoning) attended by the advanced
paramedic practitioners in a pre-hospital setting were consid-
ered eligible for inclusion. Randomisation was performed following
3 cycles of CPR regardless of return of spontaneous circulation
(ROSC). Refractory VF was deﬁned as refractory to shock and drug
treatment following 3 cycles of CPR. Patients were excluded from
the trial if at the point of randomisation they had evidence of STE
on the post-resuscitation ECG, the initial rhythm was  asystole or
pulseless electrical activity (PEA), a do not attempt resuscitation
order was in place or suspected pregnancy.
Before randomisation, patient management followed standard
pre-hospital ALS guidelines. Eligible patients were randomly allo-
cated with the use of sequentially numbered opaque, tamper-proof
sealed envelopes (sealedenvelope.com) with pre-assigned random
permuted blocks of ten, stratiﬁed according to site (advanced
paramedic car). Randomisation was performed 1:1 to one of two
parallel trial arms: intervention or control. The intervention arm
consisted of activation of the pre-hospital triaging system (cur-
rently routinely in place for STE patients only) with pre-alert and
delivery of the OHCA patient to the catheter laboratory at the ded-
icated CAC(24 h a day, 7 days a week). Patients were transported
to hospital with or without ROSC. Patients who achieved ROSC
received guideline-recommended post-resuscitation care includ-
ing targeted temperature management (36 ◦C 28 h, followed by
gradual rewarming at 0.5 ◦C per hour)24 and goal-directed thera-
pies. These included evaluation and identiﬁcation of the underlying
cause of arrest with access to immediate reperfusion if necessary
and maintenance of normocapnia and normoxia with protective
ventilation, optimisation of haemodynamics as well as mainte-
nance of normoglycaemia.25
The control arm comprised the current standard of pre-hospital
care for patients with cardiac arrest of suspected cardiac aetiology
as per LAS Cardiac Care Guidance Protocol (Supplemental data).
Patients were conveyed to the closest emergency department and
management thereafter followed standard hospital protocol. In the
absence of non-cardiac cause, and in the absence of futility, coro-
nary angiography was recommended within 48–72 h in the control
arm if not performed sooner (evidence of STE or high-suspicion of
on-going infarction at the discretion of the physician).
The primary objective of this pilot trial was to assess the feasibil-
ity of a randomised trial in OHCA without STE comparing expedited
transfer to a CAC with the current standard of care to assess a differ-
ence in 30-day mortality. Feasibility outcome measures included
recruitment rate, protocol adherence and the ability to obtain
case-report form speciﬁc data on participants. The primary clin-
ical endpoint was 30-day all-cause mortality. Secondary clinical
endpoints comprised (1) good neurological function at discharge,
capped at 30 days according to the cerebral performance category
(CPC), the most commonly used post-resuscitation outcome mea-
surement for this purpose.26 (2) The composite of in-hospital major
adverse cardiovascular events(MACE) capped at 30 days, deﬁned
as: re-infarction,27 further revascularisation and bleeding.
Prior to data analysis, the following additions were made to the
trial secondary outcomes to capture all adverse events: (1) MACE
was modiﬁed to include cerebrovascular events—termed MACCE.
(2) Sepsis, deﬁned as two  or more components of the systemic
inﬂammatory response syndrome.28
Trained research staff at St. Thomas Hospital collected trial
related data. The trial was  managed and coordinated by the London
School of Hygiene and Tropical Medicine Clinical Trials Unit (LSHTM
CTU). The study was  granted ethical approval by the United King-
dom National Research Ethics Committee (REC 13/LO/1508). Due to
the speciﬁc nature of the trial and the immediacy of the interven-
tion, the committee waived the need for prior informed consent.
At the earliest appropriate time, the participant or their legal sur-
rogate were asked for delayed consent. The trial was prospectively
registered with the International Standard Randomised Controlled
Trials Registry (ISRCTN 96585404).
Statistical analysis
Statistical analysis, based on intention to treat, was  performed
using StatPlus (AnalystSoft, USA) and Prism version 7.0 (GraphPad
Software Inc., USA). The sample size (n = 40) was selected to allow
an assessment of the feasibility of recruitment and implementa-
tion of trial processes.29 The pilot study was not powered to detect
important differences. However, categorical data were compared
using Fisher’s exact test; continuous data were compared by 2-
sample t-test. The treatment groups were compared for the primary
endpoint of all-cause mortality 30-days after randomisation using
odds ratios with 95% conﬁdence intervals (CI). The Kaplan–Meier
survival curves were drawn to assess differences between groups
for the time to an event data examining all-cause mortality at 30
days. All P values were 2 sided.
Results
Patient population and feasibility
118 cases were screened, of which 63 patients (53%) met  eligibil-
ity criteria. Forty of the 63 patients (63%) were randomised over two
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Fig. 1. Participant ﬂow diagram: as per CONSORT guidelines.
separate time periods: November 2014–March 2015 (10 patients)
and August 2015–February 2016 (30 patients). Full data were avail-
able on 36 patients (90%); reasons for exclusion are detailed in
the patient ﬂow diagram (Fig. 1), displayed according to Consol-
idated Standards of Reporting Trials (CONSORT) recommendation.
The trial was stopped at 40 patients because the planned sample
size to assess trial feasibility was reached. All randomised patients
completed the trial. All patients in the Intervention arm were deliv-
ered direct to St. Thomas Hospital cardiac catheter lab; patients in
the control arm were delivered to the emergency department (ED)
in one of 6 hospitals in London: St. Thomas Hospital, St. Mary’s
Hospital, Chelsea and Westminster Hospital, King’s College Hos-
pital, Royal Free Hospital, Royal London Hospital. One patient in
the control arm did not reach hospital (online Supplement). After
randomisation, 4 patients (10%) were found to meet exclusion cri-
teria (the presence of ST-elevation on the post-resuscitation ECG).
However, for the intention to treat analysis, all patients were ana-
lysed in the group they were randomised to regardless of this or
eventual crossover or other protocol deviation. Only one patient
was identiﬁed as having a non-cardiac cause of arrest (end-stage
renal failure) and did not survive to hospital. All other patients had
a cardiac cause of arrest. One patient had aortic dissection that was
managed within the specialist centre, ten patients were identiﬁed
as having a scar-related arrhythmia either due to previous infarct
or heart muscle disease (requiring implantable cardioverter deﬁb-
rillator implantation on admission) and the rest were directly due
to coronary artery disease.
Baseline characteristics, the intervals from cardiac arrest to
deﬁned events and ambulance service interventions are shown in
Table 1. There were no signiﬁcant differences between the two
treatment groups in terms of baseline characteristics and cardiac
arrest background variables. All patients presented with witnessed
VF out-of-hospital cardiac arrest. Three patients in each group had
ventricular ﬁbrillation that was refractory to shock and drug treat-
ment and were transported to hospital without ROSC.
Angiographic characteristics
The coronary angiographic ﬁndings are summarised in Table 2.
Time to coronary angiography was  shorter in the intervention arm
compared with the control arm (100 [75–113] versus 132 [93–187];
median difference 32, 95% CI −9 to 101; P = 0.08). The incidence of
culprit artery occlusion (responsible for the OHCA) was  44% in the
intervention group versus 50% in the control group (OR 0.6, 95% CI
0.1–2.3; P = 0.7).
Primary and secondary clinical outcomes
The primary clinical endpoint of 30-day all-cause mortality
(Table 3) was  similar between both study arms (Intervention 9/18,
50% vs. Control 6/15, 44%; OR 0.6, 95% CI 0.2–2.9; P = 0.73). Good
neurological function evaluated at discharge, capped at 30 days,
was similar in both groups (Intervention 9/18, 50% vs. Control
7/15, 47%; OR 1.1, 95% CI 0.3–4; P > 0.99) (online Supplement).
The secondary (clinical) composite endpoint of in-hospital MACCE
occurred in 11/18 in the Intervention arm compared with 6/15 in
the control arm (61% vs. 53% respectively; OR 1.4, 95% CI 0.4–4.9;
P = 0.73). One stroke occurred in the control arm, one patient in
the intervention arm and two  in the control arm underwent fur-
ther revascularisation and minor bleeding occurred in one patient
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Table 1
Angiographic characteristics of the intervention and control arm.
Total Intervention Control P value
Baseline characteristics
Age (years) 61±15 60±17 61±14 0.77
Male  31/36 (86%) 15/18 (83%) 16/18 (89%) >0.99
Hypertension 15/36 (42%) 8/18 (44%) 7/18 (39%) >0.99
Hypercholesterolemia 14/36 (39%) 8/18 (44%) 6/18 (33%) 0.73
Diabetes 6/36 (17%) 4/18 (22%) 2/18 (11%) 0.65
Previous myocardial infarction 8/36 (22%) 5/18 (28%) 3/18 (17%) 0.69
Previous PCI 5/36 (14%) 2/18 (11%) 3/18 (17%) >0.99
Previous CABG 3/36 (8%) 2/18 (11%) 1/18 (6%) >0.99
Ethnicity
Caucasian 16/36 (44%) 8/18 (44%) 8/18 (44%) >0.99
Asian  3/36 (8%) 1/18 (6%) 2/18 (11%) >0.99
Afro-Caribbean 0/36 (0%) 0/18 (0%) 0/18 (0%) >0.99
Other  4/36 (11%) 2/18 (11%) 2/18 (11%) >0.99
Unknown 5/36 (36%) 7/18 (39%) 6/18 (33%) >0.99
IHD  11/36 (31%) 6/18 (33%) 5/18 (28%) >0.99
Smoking history 7/36 (19%) 4/18 (22%) 3/18 (17%) >0.99
Event  Characteristics
Preceding symptoms 12/36 (33%) 8/18 (44%) 4/18 (22%) 0.29
Public 29/36 (81%) 14/18 (78%) 15/18 (83%) >0.99
Bystander CPR 22/36 (61%) 10/18 (56%) 12/18 (67%) 0.73
Presenting rhythm VF 36/36 (100%) 18/18 (100%) 18/18 (100%) >0.99
Refractory VF 6/36 (17%) 3/18 (17%) 3/18 (17%) >0.99
LAS  Interventions
Shock required 36/36 (100%) 18/18 (100%) 18/18 (100%) >0.99
Time  to ROSC, mins 18 (8 to 31) 16 (6 to 29) 19 (8 to 36) 0.49
Duration of resuscitation, mins 19 (7 to 31) 17 (7 to 33) 19 (7 to 31) 0.79
Number of shocks 4 (2 to 9) 3 (1 to 8) 4 (2 to 9) 0.73
Amiodarone required 20/36 (56%) 11/18 (61%) 9/18 (50%) >0.99
Amidoarone dose, mg 0 (0 to 300) 300 (0 to 300) 0 (0 to 300) 0.69
Adrenaline required 21/36 (58%) 11/18 (61%) 10/18 (56%) >0.99
Adrenaline dose, mg  1 (0-6) 1 (0 to 8) 2 (0 to 6) 0.75
Pre-hospital ROSC 28/36 (78%) 14/18 (78%) 14/18 (78%) >0.99
Intubated 15/36 (42%) 10/18 (56%) 5/18 (28%) 0.18
GCS  on arrival 3 (3 to 10) 3 (3 to 4) 4 (3 to 14) 0.19
Mechanical CPR 17/36 (47%) 9/18 (50%) 8/18 (44%) >0.99
ECG  characteristics
12 lead 27/36 (75%) 13/18 (72%) 14/18 (78%) >0.99
ST  elevation 4/36 (11%) 3/18 (17%) 1/18 (6%) 0.6
Table 2
Angiographic characteristics of the intervention and control arm.
Total Intervention Control P value
Angiogram 32/36 (89%) 18/18 (100%) 14/18 (78%) 0.10
Time  to Angiography (minutes) 100; 75–113 132; 93–187 0.08
Coronary Artery Disease (>50% stenosis) 20/32 (63%) 12/18 (67%) 8/14 (57%) 0.72
Number of diseased vessels
0 10/32 (31%) 6/18 (33%) 4/14 (21%) >0.99
1  4/32 (13%) 2/18(11%) 2/14 (14%) >0.99
2  4/32 (13%) 2/18(11%) 2/14 (14%) 0.47
≥3  12/32 (38%) 8/18 (44%) 4/14 (29%) 0.47
Unknown 2/32 (6%) 0/32 (0%) 2/14 (6%) 0.18
Culprit: Revascularisation 15/32 (47%) 8/18 (44%) 7/14 (50%) 0.71
1.  PCI 13/15 (87%) 7/8 (88%) 6/7 (86%) >0.99
LMS  0/13 (0%) 0/7 (0%) 0/6 (0%) >0.99
LAD  5/13 (38%) 3/7 (43%) 2/6 (33%) >0.99
Cx  3/13 (23%) 1/7 (14%) 2/6 (33%) 0.56
RCA  5/13 (38%) 3/7 (43%) 2/6 (33%) >0.99
2.  CABG 2/15 (13%) 1/8 (13%) 1/7 (14%) >0.99
Cardiac arrest event characteristics, time intervals from cardiac arrest to deﬁned events and London ambulance service (LAS) interventions for the pilot trial. Categor-
ical  variables are presented as counts and percentages n/N (%); age is presented as mean ± SD; times, Glasgow coma scale (GCS) and drug dosages are displayed as
median  (interquartile range, IQR). Abbreviations: PCI percutaneous coronary intervention, CABG coronary artery bypass graft surgery, IHD ischaemic heart disease, CPR
cardiopulmonary resuscitation, VF ventricular ﬁbrillation, ROSC return of spontaneous circulation, GCS Glasgow coma scale, ECG electrocardiogram.
in the intervention arm. The secondary endpoint of 6-month all-
cause mortality was 9/17 (53%) in the intervention arm and 6/10
(60%) in the control arm (OR 0.75, 95% CI 0.2–3.8; P > 0.99). One
third of patients in both groups developed sepsis. Vascular compli-
cations occurred in one patient in the control arm. Four patients
in the intervention group and two patients in the control group
required mechanical circulatory support in the form of intra-aortic
balloon pump insertion. Length of stay was  the same in the two
groups (intervention: 4.5, versus control: 4.5, median difference 0,
95% CI −2 to 8; P = 0.19).
The Kaplan–Meier 30-day survival curve is shown in Fig. 2
(intervention versus control: HR 1.7, 95% CI 0.3–10.5; P = 0.6). In
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Table  3
Primary and secondary outcomes, length of stay and other in-hospital complications described overall and for both arms of the trial.
Total Intervention Control OR (95% CI)a P value
Primary endpoint
30-day all cause mortality 15/33 (45%) 9/18 (50%) 6/15 (40%) 0.6 (0.2–2.9) 0.73
Secondary endpoints
CPC 1/2 at 30 days 16/32 (50%) 9/18 (50%) 7/14 (50%) 1.0 (0.3–3.6) >0.99
MACCE* 19/33 (58%) 11/18 (61%) 8/15 (53%) 1.4 (0.4–4.9) 0.73
Death 15/33 (45%) 9/18 (50%) 6/15 (40%) 0.6 (0.2–2.9) 0.73
MI  0/33 (0%) 0/18 (0%) 0/15 (0%) N/A >0.99
Further revascularization 3/33 (9%) 1/18(6%) 2/15 (13%) 0.4 (0–3.7) 0.58
Stroke  1/33 (3%) 1/18 (6%) 0/15 (0%) N/A >0.99
Bleeding 1/33(3%) 1/18 (6%) 0/15 (0%) N/A >0.99
Vascular complications 1/33 (3%) 0/18 (0%) 1/15 (7%) 0 (0–7.5) 0.5
6-month all cause mortality 15/27 (56%) 9/17 (53%) 6/10 (60%) 0.75 (0.2–3.8) >0.99
Length of staya 4.5 (0–11) 4.5 (0–7.3) 4.5 (0–19) 0 (−2 to 8) 0.19
CPR  related complications 1/33 (3%) 1/18 (6%) 0/15 (0%) N/A >0.99
Renal  replacement therapy 2/33 (3%) 1/18 (6%) 1/15 (7%) 0.8 (0–17) >0.99
Sepsis 11/33 (33%) 6/18 (33%) 5/15 (33%) 1.0 (0.2–4.5) >0.99
Mechanical circulatory support 6/33 (18%) 4/18 (22%) 2/15 (13%) 1.6 (0.3–9.5) 0.68
Categorical variables are presented as counts and percentages n/N (%). Abbreviations:  CPC cerebral performance category score, MACCE major adverse cardiovascular and
cerebrovascular events, CPR cardiopulmonary resuscitation.
a Days are displayed as median and interquartile range (IQR).
Fig. 2. Survival curves for the whole cohort of 40 patients. Event rate was  calculated
by  Kaplan–Meier method; survivor function (solid line) and survival rates accord-
ing  to randomization arm: Intervention (dotted line), Control (broken line) Event
rates were calculated by the Kaplan–Meier method, HR 1.7 (95% CI 0.3–10.5) and
compared with the use of the Log-rank test P = 0.6.
both study arms, a marked attrition in survival was seen between
Day 0 and Day 4, with 25% of patients dead in the Intervention arm
and 17% in the Control arm (overall 21%). No further patients died
between day 4 and day 30. Administration of amiodarone was  asso-
ciated with increased 30-day mortality (HR 11.5, 95% CI 1.04–126;
P = 0.04). Pre-hospital ROSC (HR 0.1, 95% CI 0.01–0.7; P = 0.02), and
cardiac arrest in a public location (HR 0.05, 95% CI 0.004–0.45;
P = 0.01) were associated with a lower mortality. The performance
of coronary angiography was found to negatively inﬂuence 30-
day mortality (HR 0.15, 95% CI 0.03–0.71; P = 0.02); however, after
adjustment for pre-hospital factors, there was no inﬂuence on 30-
day mortality (HR 0.41, 95% CI 0.05–3.5; P = 0.4), Fig. 3.
Discussion
We  demonstrated that it is possible to complete a randomised
controlled trial comparing a pre-hospital triage system involving
delivery of the OHCA patient to a CAC with access to 24/7 interven-
tional cardiology facilities and receipt of a post-cardiac arrest care
bundle with the current standard of care in a population of OHCA
patients without STE. The main ﬁnding of this pilot trial is that per-
Fig. 3. Cox proportional hazards model, presented as a forest plot, for predictors for
30-mortality; abbreviations: ROSC return of spontaneous circulation, MI  myocardial
infarction, PCI percutaneous coronary intervention.
forming a large-scale randomised controlled trial is safe, feasible
and acceptable. The feasibility of randomisation was demonstrated
as follows: (1) recruitment of all adult witnessed shockable OHCA
of presumed cardiac cause exceeded the expected rate. (2) It was
possible to set up a fast track, rapid intervention service in a single
CAC 24/7. (3) Protocol adherence was  excellent in the intervention
arm. (4) Data completeness was  acceptable with documentation of
the primary outcome in 83% and secondary outcomes in 80%.
Based on the ﬁndings of the trial pilot, the decision to exclude
the refractory cohort from the main trial was made based on (1)
logistical challenges of on-scene extrication, transport and per-
forming coronary angiography during mechanical CPR (m-CPR). (2)
Poor outcomes relative to the cohort of patients achieving ROSC.
(3) The identiﬁcation that this was a predictor of 30-day mortal-
ity. Furthermore, not all frontline vehicles carry m-CPR devices,
which may  prevent shock-refractory patients receiving the same
treatment in the main trial. The PARAMEDIC trial (LUCAS m-CPR
device) showed a 5% lower survival rate (signiﬁcant) in patients
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with shockable rhythms who received mechanical CPR, although
this was not the primary objective of the trial, and should be inter-
preted with caution.30 Furthermore, removal of this cohort will
reduce the likelihood of post randomisation identiﬁcation of STE
(10%).
Outcome was ascertained in 83%; to improve this we will make
use of the NHS information centre; in the PARAMEDIC trial, this
enabled 99% follow-up at 30-days.30 Where data cannot be col-
lected in hospital we plan to make use of the London Ambulance
Clinical Audit and Research Unit (CARU) and National Institute for
Cardiovascular Outcomes Research (NICOR). Because of the geo-
graphical position of St. Thomas Hospital, a large proportion of the
standard of care arm were delivered to a CAC; we anticipate that
expanding the trial across London will reduce the proportion of
patients in the control arm taken straight to the cardiac catheteri-
sation laboratory.
The International Liaison Committee on Resuscitation (ILCOR)
suggests transport of all post-arrest patients to a cardiac arrest
centre with 24/7 access to interventional cardiology facilities.19–22
There has been variable uptake of such a strategy in this cohort; this
may  be due in part to the lack of randomised data, the need for coor-
dination of organised systems of care, and the heterogeneity of the
non-STE population; thus emphasising the need for a randomised
controlled trial.
Our study is consistent with well-established predictors of sur-
vival, including ROSC pre-hospital and cardiac arrest in a public
location. The predictor of mortality identiﬁed was administration
of amiodarone, this is likely to represent refractory arrhythmia
rather than the effect of amiodarone itself. These are supported
by ﬁndings in the recently published “amiodarone versus ligno-
caine and placebo trial in OHCA”, where no difference in survival
was shown, with a higher mortality in those with unwitnessed
arrest.31 Coronary angiography was performed in all patients in
the intervention group and just under 80% of control, suggesting
that coronary angiography was clinically indicated in the latter.
The time to coronary angiography was shorter in the interven-
tion arm because of immediate delivery to a CAC, but this did not
reach statistical signiﬁcance in these few patients. In those who
underwent coronary angiography, signiﬁcant coronary disease was
identiﬁed in two thirds of patients, with a culprit lesion in just over
half, which is consistent with published registry data.16,32 How-
ever should be interpreted with caution because this was a small
patient cohort that may  not be representative of the patient pop-
ulation.The ﬁndings from this pilot also suggest that the absence
of STE on the post-arrest ECG does not exclude acute ischemia.15
The overall mortality, albeit low, is representative of the VF OHCA
population that achieves ROSC pre-hospital and is consistent with
previous ﬁgures published by the London Ambulance Service.33
Limitations
This study was a pilot randomised trial to demonstrate safety
and feasibility; the study was not powered to show a difference in
30-day mortality, neurological endpoints or the composite of in-
hospital MACCE. The full planned trial with a sample size of 860,
will aim to address these questions. The catchment area around
St. Thomas Hospital was small and may  not be representative of
the population. Although this pilot provided an indication of the
underlying event rate and incidence of occlusive coronary artery
disease, the effect size and therefore sample size calculations were
based on a combination of studies. These included the above pilot
ﬁndings, Pan-London Annual OHCA audit data, published registry
data (incidence of occlusive disease in OHCA in absence of STE) and
randomised trials of reperfusion therapy.13,33–35 Based on ﬁndings
from the trial pilot, inclusion criteria were amended to remove
the shock-refractory cohort from the main trial because logisti-
cal challenges of managing these patients, and in order to reduce
the likelihood of post-randomisation identiﬁcation of STE. Delayed
prognostication (≥72 h) to prevent the premature withdrawal of
life-sustaining treatment was not formally instituted in the pilot
as this was  not the current standard of care; however this will be
mandated during the full trial.36
Conclusions
This pilot study demonstrated that a large-scale randomised
trial comparing the delivery of a cardiac arrest patient without
STE to the catheter laboratory at a dedicated cardiac arrest receiv-
ing centre with a view to immediate reperfusion and delivery of
post-resuscitation care, compared with standard care, is safe and
feasible.
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